Research programme: bispecific antibodies - Lyvgen Biopharma
Alternative Names: PD-1 + Target XsLatest Information Update: 03 Feb 2021
Price :
$50 *
At a glance
- Originator Lyvgen Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Jan 2021 Research programme: bispecific antibodies - Lyvgen Biopharma is available for licensing as of 12 Jan 2021. https://www.lyvgen.com/pipeline
- 12 Jan 2021 Early research in Cancer in China (Parenteral)